Literature DB >> 22246671

Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership.

Scott J Weir1, Louis J DeGennaro, Christopher P Austin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22246671      PMCID： PMC3341848          DOI： 10.1158/0008-5472.CAN-11-3439

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  Building a stronger foundation for a new century of treatments and cures.

Authors:  Kathleen Sebelius
Journal:  Health Aff (Millwood)       Date:  2011-01       Impact factor: 6.301

2.  Mining for therapeutic gold.

Authors:  Francis S Collins
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

3.  Reengineering translational science: the time is right.

Authors:  Francis S Collins
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956
  3 in total
  37 in total

1.  Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma.

Authors:  Marta Celegato; Cinzia Borghese; Naike Casagrande; Maurizio Mongiat; Xaver U Kahle; Alice Paulitti; Michele Spina; Alfonso Colombatti; Donatella Aldinucci
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

2.  Drug repurposing for gastrointestinal stromal tumor.

Authors:  Ziyan Y Pessetto; Scott J Weir; Geetika Sethi; Melinda A Broward; Andrew K Godwin
Journal:  Mol Cancer Ther       Date:  2013-05-08       Impact factor: 6.261

Review 3.  Drug repurposing in oncology--patient and health systems opportunities.

Authors:  Francesco Bertolini; Vikas P Sukhatme; Gauthier Bouche
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

4.  Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.

Authors:  Ziyan Y Pessetto; Yan Ma; Jeff J Hirst; Margaret von Mehren; Scott J Weir; Andrew K Godwin
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

5.  The antimalarial amodiaquine causes autophagic-lysosomal and proliferative blockade sensitizing human melanoma cells to starvation- and chemotherapy-induced cell death.

Authors:  Shuxi Qiao; Shasha Tao; Montserrat Rojo de la Vega; Sophia L Park; Amanda A Vonderfecht; Suesan L Jacobs; Donna D Zhang; Georg T Wondrak
Journal:  Autophagy       Date:  2013-10-08       Impact factor: 16.016

6.  Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Authors:  Vikram B Wali; Casey G Langdon; Matthew A Held; James T Platt; Gauri A Patwardhan; Anton Safonov; Bilge Aktas; Lajos Pusztai; David F Stern; Christos Hatzis
Journal:  Cancer Res       Date:  2016-11-21       Impact factor: 12.701

Review 7.  Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.

Authors:  Nathan P Coussens; John C Braisted; Tyler Peryea; G Sitta Sittampalam; Anton Simeonov; Matthew D Hall
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

8.  KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.

Authors:  Bingbing Dai; Suk-Young Yoo; Geoffrey Bartholomeusz; Ryan A Graham; Mourad Majidi; Shaoyu Yan; Jieru Meng; Lin Ji; Kevin Coombes; John D Minna; Bingliang Fang; Jack A Roth
Journal:  Cancer Res       Date:  2013-07-03       Impact factor: 12.701

9.  Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.

Authors:  Michelle Kiebala; Jolanta Skalska; Carla Casulo; Paul S Brookes; Derick R Peterson; Shannon P Hilchey; Yun Dai; Steven Grant; Sanjay B Maggirwar; Steven H Bernstein
Journal:  Exp Hematol       Date:  2014-10-22       Impact factor: 3.084

10.  Drug Repurposing for Cancer Therapy.

Authors:  Carlos M Telleria
Journal:  J Cancer Sci Ther       Date:  2012-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.